Medipharm Labs (LABS.TO) Stock Price
Medipharm Labs Price
Revenue at Medipharm Labs has contracted by 16.1% per year over the past 6 years to 45.12 M CAD. For Medipharm Labs, the net margin of -18.3% is up versus -252.4% a few years ago. The consensus 12-month price target for Medipharm Labs is 0.10 CAD, about 56.9% above where the stock trades today. Of 10 analysts, 0 rate the stock a buy — an overall Sell consensus.
Medipharm Labs stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Medipharm Labs business model & stock analysis
Frequently asked questions about Medipharm Labs
Medipharm Labs Corp's business model revolves around being a leading pharmaceutical company in the cannabis industry. They specialize in producing high-quality, pharmaceutical-grade cannabis oil and concentrates through their state-of-the-art extraction facilities. Medipharm Labs Corp follows a B2B (business-to-business) approach, providing extraction, purification, and white-label product manufacturing services to licensed producers and brands worldwide. Their strict adherence to cGMP (current Good Manufacturing Practices) and ISO standards ensures consistent, safe, and reliable products for their clients. By offering expertise in extraction and product formulation, Medipharm Labs Corp plays a vital role in the broader cannabis supply chain, helping brands offer innovative and differentiated cannabis products to consumers.
Medipharm Labs Corp is primarily active in the cannabis and pharmaceutical industries.
Medipharm Labs Corp operates in a competitive market that includes several cannabis extraction companies. Some key competitors of Medipharm Labs Corp are Canopy Growth Corporation, Aphria Inc., and Aurora Cannabis Inc.
Medipharm Labs Corp is a leading global pharmaceutical company specializing in the production and distribution of high-quality cannabis-based products. Founded in 2015, the company quickly emerged as a pioneer in the cannabis industry, leveraging its state-of-the-art facilities and advanced extraction methods to produce pharmaceutical-grade cannabis oil and purified derivatives. Medipharm Labs has established itself as a trusted partner for licensed producers and manufacturers worldwide, offering expertise in extraction, purification, and formulation of cannabis products. With a strong commitment to quality and innovation, Medipharm Labs Corp continues to shape the future of the cannabis industry with its cutting-edge solutions and strategic partnerships.
Medipharm Labs Corp has achieved several significant milestones. One notable achievement is their listing on the Toronto Stock Exchange (TSX) under the ticker symbol "LABS." The company has also received its Health Canada license for cannabis extraction, enabling them to operate as a licensed producer of cannabis extracts. Medipharm Labs Corp has established a reputation for producing high-quality pharmaceutical-grade cannabis oil and concentrates, earning them the trust and support of customers and investors alike. Additionally, the company has formed strategic partnerships with leading cannabis brands, expanding its market reach and ensuring long-term growth prospects. Overall, Medipharm Labs Corp has made meaningful strides in the cannabis industry, positioning itself as a trusted and innovative player in the market.
Medipharm Labs Corp is primarily present in Canada. As a leading cannabis extraction company, Medipharm Labs is headquartered in Ontario, Canada. With a strong focus on research, development, and production of pharmaceutical-grade cannabis oil, the company operates its state-of-the-art facilities in Canada, supplying the legal international cannabis market. Medipharm Labs has established a reputation for producing high-quality, pure, and safe cannabis oil products, meeting the stringent regulatory requirements in Canada. Through its strategic partnerships and distribution channels, Medipharm Labs continues to expand its presence and brand recognition both domestically and internationally.
Medipharm Labs Corp represents values of innovation, integrity, and excellence in the cannabis industry. With its focused corporate philosophy, the company emphasizes on producing high-quality, pharmaceutical-grade cannabis products. Medipharm Labs Corp is dedicated to operating with transparency and regulatory compliance, ensuring the safety and well-being of its customers. The company's strong commitment to research and development enables them to continuously improve and offer cutting-edge cannabinoid-based solutions. As a leading provider of cannabis extraction services, Medipharm Labs Corp aims to deliver reliable and consistent products to meet the evolving needs of medical patients and adult-use consumers.
Analysts currently set an average price target of 0.10 CAD for the Medipharm Labs stock (median: 0.10 CAD), implying +56.9 % versus the latest price. The consensus is based on 10 analyst ratings.
9 analysts currently rate the Medipharm Labs stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect Medipharm Labs to generate revenue of 38.98 M CAD and earnings per share of -0.01 CAD.
Converted at the current exchange rate, the Medipharm Labs share trades at 0.04 EUR (0.06 CAD).
The Medipharm Labs share (LABS.TO) is listed on 5 stock exchanges, including: Toronto (LABS.TO), Frankfurt (MLZ.F), München (MLZ.MU), Düsseldorf (MLZ.DU).
MediPharm Labs Corp is a leading specialized manufacturer of high-quality pharmaceutical products based on cannabis. The company is one of the few licensed producers in Canada specializing in the extraction of pure cannabinoids while adhering to strict industry quality standards. The business model of MediPharm Labs Corp focuses on the production of high-quality pharmaceutical products using cannabis extracts and other cannabinoid-containing raw materials. The company's products are used in various areas such as medicine, cosmetics, the food industry, as well as wellness and lifestyle products. MediPharm Labs Corp offers a wide range of products made from pure cannabis extracts. These include THC and CBD oils, concentrated cannabis extracts, full-spectrum extracts, and other cannabinoid-based products. These products are available in various concentrations and forms such as tinctures, gel capsules, sprays, and vaporizer cartridges. MediPharm Labs Corp has also expanded its business to the production of white-label products. These are products marketed under the customer's own brand. The company offers a complete range of services, from sourcing raw materials to packaging design. Another important part of MediPharm Labs Corp's business model is collaboration with other companies and organizations in the industry. Through partnerships with other manufacturers, research institutions, and government agencies, the company is able to expand its knowledge and experience in the industry and further improve its products and services. MediPharm Labs Corp has also developed a strong presence in Canada and is one of the leading brands in this market. However, the company also plans to expand internationally into other countries, particularly in Europe and Asia. In summary, MediPharm Labs Corp's business model is based on the production of high-quality pharmaceutical products based on cannabis extracts. The company has expanded its offerings to various areas such as medicine, cosmetics, food, and lifestyle products, and also offers white-label services. The company operates strong marketing and plans for international expansion.
The expected revenue of Medipharm Labs is 38.98 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Medipharm Labs is -4.08 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medipharm Labs is currently -6.70. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medipharm Labs stock.
The price-to-sales ratio (P/S) of Medipharm Labs is currently 0.70. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medipharm Labs stock.
The Eulerpool Quality Score for Medipharm Labs is 3/10.
The ISIN of Medipharm Labs is CA58504D1006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medipharm Labs is A2N7AA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medipharm Labs is LABS.TO. The ticker symbol is used to trade Medipharm Labs shares on the stock exchange.
Medipharm Labs stock
Medipharm Labs Peer Group
Medipharm Labs Ticker
Medipharm Labs FIGI
All fundamentals and in-depth analysis of Medipharm Labs
Our stock analysis for Medipharm Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medipharm Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.